ALK Inhibitor Outperforms Adjuvant Chemotherapy for Resected Lung Cancer
Adjuvant alectinib reduces disease-free survival hazard by 76%
Source: medpagetoday.com
Stay updated with breaking news from Benjamin Solomon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adjuvant alectinib reduces disease-free survival hazard by 76%
Adjuvant alectinib can improve disease-free survival, when compared to adjuvant chemotherapy, in patients with ALK+ NSCLC.
The statistically significant and clinically meaningful improvement in disease-free survival is “practice-changing” and may represent a “paradigm shift” in treatment, according to experts.